Acute Myeloid Leukemia Study
COG #AAML0531: A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
Protocol ID
Protocol Description
The goals of this study are:
1. To see if adding a new drug, called gemtuzumab to the current standard treatment for acute myeloid leukemia (AML) will improve the cure rate without causing more serious side effects
2. To compare the outcomes of children who have higher risk disease and receive a stem cell transplant to children who don’t have higher risk disease
3. To evaluate how well children with Down syndrome (who are over 4 years old) do when they receive the standard chemotherapy without gemtuzumab
4. To understand the biology of AML better with optional biology tests
Eligibility Criteria
Children and adolescents diagnosed with acute myeloid leukemia (AML)
Primary Investigator(s)
- Arlene Redner, MD